Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
02
08
2018
revised:
05
02
2019
accepted:
25
02
2019
pubmed:
12
5
2019
medline:
9
6
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.
Identifiants
pubmed: 31076244
pii: S1474-4422(19)30144-9
doi: 10.1016/S1474-4422(19)30144-9
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
784-794Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.